Bottom line
Is IHE a good fund? The bottom line
IHE is a managed health care sector ETF from iShares.
Annual fees run 0.37% — about $37 a year on every $10,000 invested, cheaper than 87% of health care sector funds we track.
It returned +31.7% over one year, +9.1% a year over five years, +6.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.1 billion in net assets and 59 holdings, its largest position is Johnson & Johnson (22.4%) and the top 10 make up 79.5% of the portfolio.
What stands out
- Low cost: cheaper than 87% of health care sector peers
- 5-year return beat 96% of category peers
What to watch
- Concentrated: top 10 holdings are 79.5% of assets
Updated Nov 19, 2026
What IHE invests in
The iShares U.S. Pharmaceuticals ETF (the Fund ) seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector.
The Fund seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index (the Underlying Index ), which measures the performance of the pharmaceuticals sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC (the Index Provider or SPDJI ). The Underlying Index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The Underlying Index may include large-, mid- or small-capitalization companies. As of March 31, 2026, a significant portion of the Underlying Index was represented by securities of companies in the healthcare and pharmaceuticals industries or sectors. The components of the Underlying Index are likely to change over time. The Fund seeks to track the investment results of the Underlying Index before fees and expenses of the Fund. BFA uses a representative sampling indexing…
From the fund's prospectus (filed Jul 27, 2026).
IHE performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| IHE | +31.7% | +9.1% | +6.2% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What IHE costs
On a $10,000 investment, IHE's 0.37% expense ratio costs about $37 a year. The prospectus estimates $468 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
IHE top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Johnson & Johnson | 22.44% |
| 2 | Eli Lilly And Company | 22.25% |
| 3 | BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 6.24% |
| 4 | Merck & Co., Inc. | 4.55% |
| 5 | Bristol-myers Squibb Company | 4.37% |
| 6 | Royalty Pharma Plc | 4.34% |
| 7 | Viatris Inc. | 4.22% |
| 8 | Pfizer Inc. | 3.96% |
| 9 | Zoetis Inc. | 3.73% |
| 10 | Jazz Pharmaceuticals Public Limited Company | 3.45% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 79.5% of the fund. See all top 25 holdings and asset mix →